The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Abstract The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines
Committee provides periodic reviews of new data to produce focused updates that address …

Background—Evidence regarding the use of direct oral anticoagulants (DOACs) in the
elderly, particularly bleeding risks, is unclear despite the presence of greater comorbidities …

Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular
atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major …

The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Aim To assess persistence and adherence to rivaroxaban, dabigatran, and vitamin K
antagonist (VKA) treatment in primary care patients with non-valvular atrial fibrillation (AF) …